1. Gary K. Schwartz, MD

    • Department of Medicine
      Division of Hematology/Oncology
    Headshot

    I am a board-certified medical oncologist and internist and chief of Columbia University Medical Center's Division of Hematology and Oncology. I am actively involved in translational and clinical research. The lab, which I direct, focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of sarcoma and melanoma. However, these agents are not disease specific and hold promise in the treatment of all solid-tumor malignancies. These laboratory studies allow for a bridge between the laboratory and the clinic, and many of these drugs that originated in the lab are now being evaluated in clinical trials. My research studies have been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the Food and Drug Administration.

    I am active in a number of professional organizations, including ALLIANCE for Clinical Trials in Oncology, the American Association of Cancer Research, the American Society of Clinical Oncology, and Radiotherapy Oncology Group. For several years, I have worked closely with the National Institutes of Health and served on a number of NIH review committees. Over the course of my career, I have received many awards, including the Lustgarten Foundation for Pancreatic Research, Jeannik M. Littlefield-AACR Award in Metastatic Colon Cancer and the New York State Teaching Award in the Empire Clinical Research Investigator Program. I have also been awarded a K12 award from the NCI for the training of the next generation of physician-scientists in cancer therapy. I am involved in the teaching and mentorship of junior faculty and fellows, and I take great pride in my active participation in patient care.

    I have served on the editorial boards of a number of scientific journals, and I serve as associate editor on both the Journal of Clinical Oncology and Clinical Cancer Research. I am the author of nearly 200 papers and 17 book chapters.

    Honors and Awards

    • 2013 MSKCC Fellowship Solid Tumor Teach Award
    • 2009 Memorial Sloan-Kettering Teaching Excellence Award
    • 2006 New York State Teaching Award–Empire Clinical Research Investigator Program
    • 2006 Jeannik M. Littlefield–AACR Award in Metastatic Colon Cancer
    • 2003 Lustgarten Foundation for Pancreatic Research
    CUMC crown logoGary K. Schwartz, MD
    is accepting new patients.
    Call (212) 305-5098 for appointments.

    Provider Information

    Rated one of New York Magazine's Best Doctors
    Rated One of New York Magazine's
    Best Doctors.

    Board Certifications

    • Medical Oncology
    • Internal Medicine

    Clinical Expertise

    • Cancer Care
    • Internal Medicine
    • Leiomyosarcoma
    • Medical Oncology
    • Melanoma
    • Sarcoma

    Hospital Affiliations

    • NewYork-Presbyterian/Columbia
    • NewYork-Presbyterian/Lawrence Hospital

    Primary Location

    • Herbert Irving Pavilion

      161 Fort Washington Avenue
      Floor: 9
      New York, NY 10032
      Phone:
      (212) 305-2055
      For new and current patient appointments, call:
      (212) 305-5098
      Fax:
      (212) 305-6891

    Insurance Programs

    Please contact the provider’s office directly to verify that your particular insurance is accepted.
    • Aetna [EPO, HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
    • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
    • Amida Care
    • Cigna [EPO, Great West, HMO, POS, PPO]
    • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
    • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
    • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
    • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Local 1199
    • MagnaCare
    • Multiplan
    • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
    • POMCO
    • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
    • VNSNY CHOICE [SelectHealth]

    Biographical Detail

    Academic Appointments

    • Professor of Medicine at CUMC

    Current Administrative Positions

    • Division Chief, Hematology/Oncology
    • Associate Director, Herbert Irving Comprehensive Cancer Center

    Education And Training

      Education & Training

    • MD, Albany Medical College
    • Albany Medical College
    • Residency: North Shore University Hospital
    • Fellowship: Mount Sinai Hospital

    Gender

    Male

    Positions

    01/2006–12/2013
    Memorial Sloan-Kettering Cancer Center, Dept. of Medicine  New York, NY
    Chief Attending, Melanoma-Sarcoma Oncology Service

    05/2005–12/2013
    Memorial Sloan-Kettering Cancer Center, Dept. of Medicine  New York, NY
    Attending Physician, Memorial Hospital for Cancer and Allied Diseases
    Professor of Medicine, Weill Cornell Medical College (2/1/2006)
    Member

    09/1998–05/2005
    Memorial Sloan-Kettering Cancer Center, Dept. of Medicine  New York, NY
    Associate Attending Physician, Memorial Hospital for Cancer and Allied Diseases
    Associate Professor, Weill Cornell Medical College (6/1/2001)
    Associate Member

    09/1993-09/1998
    Memorial Sloan-Kettering Cancer Center, Dept. of Medicine  New York, NY
    Assistant Attending Physician, Memorial Hospital for Cancer and Allied Diseases
    Assistant Professor, Weill Cornell Medical College
    Assistant Member

    07/1990-09/1993
    Memorial Sloan-Kettering Cancer Center, Dept. of Medicine  New York, NY
    Clinical Assistant Physician, Memorial Hospital for Cancer and Allied Diseases
    Instructor, Weill Cornell Medical College

    1990
    Mount Sinai School of Medicine, Dept. of Neoplastic Diseases  New York, NY
    Assistant Professor

    1998-1990
    Mount Sinai School of Medicine, Dept. of Neoplastic Diseases  New York, NY
    Clinical Assistant Physician and Instructor

    Committee/societies Council Memberships

    Memberships and Positions

    • 2013–present:  Member, ASCO Cancer Education Committee – Sarcoma Track
    • 2012–present:   Member, ASCO Cancer Communications Committee
    • 2012:  Member, 2012 Clinical Scholar and Young Investigators Award Committee (Alliance for Clinical Trials in Oncology Foundation)
    • 2011–present:  Co-Chair, Experimental Therapeutics Committee, Alliance
    • 2011:  Member, Melanoma Foundation Grant Review Committee
    • 2010–present:  Member, NCI’s Experimental Therapeutics Program (NExT)
    • 2009–2011: Member, ASCO Grant Selection Committee


    Editorial

    • 2013-Present: Associate Editor, Journal of Clinical Oncology
    • 2011: Associate Editorial Board Member, Frontiers in Pharmacology of Anti-Cancer Drugs
    • 2011: Editorial Board Member, Drug Discoveries & Therapeutics
    • 2011: Editorial Board Member, Investigational New Drugs
    • 2003-2006: Editorial Advisory Board, Cancer
    • 2000-Present: Associate Editor, Clinical Cancer Research
    • 2004-2008: Editorial Board Member, Journal of Clinical Oncology
  2. Research Information

    Research Interests

    • Melanoma
    • Sarcoma
    • Drug Development

    Grants

    Present Support               

    • 2013–2014:  Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma; Principal Investigator; $300,000;Starr Cancer Consortium 15-A616
    • 2011–2015:  A Phase II Study of Pazopanib in Conjunction with Gemcitabine and Docetaxel (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS);Co-PI; $279,536; NCCN
    • 2010–2015: Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma; PI – Project 2; $205,612; Co-Director; Administrative Core; $112,340; NIH P50CA140146-03
    • 2010–2014: Development of Targeted Therapies for Ga/11 Mutant Melanoma; Co-Investigator; $150,000; Melanoma Research Alliance (MRA)
    • 2009–2014: Developing New Strategies for Targeting mTOR and IGF-1R/PI3/AKT Pathways in Sarcoma; Principal Investigator; $374,288; NIH R01 CA140331-04
    • 1995–2014: Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis; Co-Investigator; $135,153; U01 CA069856-16

    Grants/Contracts

    • A PHASE 1 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING ORAL DOSES OF THE GLUTAMINASE INHIBITOR CB 839, AS SINGLE AGENT AND IN COMBINATION WITH STANDARD CHEMOTHERAPY IN PATIENTS WITH ADVANCED (P&S Industry Clinical Trial)

      Mar 5 2015 - Mar 5 2020

      A PHASE IB/II, MULTICENTER, OPEN LABEL, STUDY OF LEE011 IN COMBINATION WITH MEK162 IN ADULT PATIENTS WITH NRAS MUTANT MELANOMA (P&S Industry Clinical Trial)

      Oct 23 2014 - Oct 23 2019

      A PHASE 1/1B STUDY OF MGCD516 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES (P&S Industry Clinical Trial)

      Oct 8 2014 - Oct 8 2019

      A PHASE 1 MULTIPLE ASCENDING DOSE STUDYOF DS-3032B, AN ORAL MDM2 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS OR (P&S Industry Clinical Trial)

      Sep 5 2014 - Sep 5 2019

      EXPANDED ACCESS OF MK-3475 IN METASTATIC MELANOMA PATIENTS WITH LIMITED TO NO TREATMENT OPTIONS (P&S Industry Clinical Trial)

      Aug 14 2014 - Aug 14 2019

      A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY OF SELUMETINIB (AZD6244, HYD-SULFATE) IN COMBINATION WITH DACARBAZINE COMPARED WITH PLACEBO (P&S Industry Clinical Trial)

      Aug 8 2014 - Aug 8 2019

      COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)

      Aug 1 2014 - Jul 31 2019

      CANCER CENTER SUPPORT GRANT (Federal Gov)

      Jul 1 2014 - Jun 30 2019

      PHASE 1 A/1 B STUDY OF 11-1 F4 MAB FOR THE TREATMENT OF AL AMYLOIDOSIS (Federal Gov)

      Sep 10 2015 - Jun 30 2018

      DEVELOPMENT OF SGL-110 FOR THE TREATMENT OF BILLIARY CANCERS (Private)

      Dec 1 2014 - Dec 31 2016

      ALLIANCE FOR CLINICAL TRIALS MASTER AGREEMENT (Private)

      Aug 6 2014 - Aug 5 2016

      DEVELOPING NEW STRATEGIES FOR TARGETING MTOR AND IGF-1R/P13K/AKT PATHWAYS IN SARC (Federal Gov)

      Jan 1 2014 - Jun 30 2015

      PROJECT 2: DEVELOPING NEW STRATEGIES FOR TARGETING PDBFR/P13K/AKT PATHWAYS IN SARCOMA (Federal Gov)

      Jan 1 2014 - Jun 30 2015

  3. publications

    • Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288(6):3804-15. PMCID: 3567635.
    •  Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model. Mol Cancer Ther. 2013.
    • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. PMCID: 3766955.
    • Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):2024-8. PMCID: 3661937.
    • Dickson MA, Okuno SH, Keohan ML, Maki RG, D'Adamo DR, Akhurst TJ, Antonescu CR, Schwartz GK. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24(1):252-7.
    • Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther. 2013;12(5):768-76. 
    • Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res. 2012;18(9):2638-47. PMCID: 3343204.
    • Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, Ladanyi M, Schwartz GK. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012;72(17):4515-25. PMCID: 3432680.
    • Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One. 2012;7(7):e40439. PMCID: 3393714.
    • Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862-8. PMCID: 3111206.
    • Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.

    For a complete list of publications, please visit PubMed.gov